Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Investor Wire

EXEL Quote, Trading Chart, Exelixis Inc.


home / stock / exel / exel quote

$22.33 Last:

4.79% Change Percent:

$21.5 Open:

$22.33 Previous Close:

$22.35 High:

$21.08 Low:

1,995,437 Volume:

03/05/2021 04:55:29 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2021-03-0521.522.3322.3521.081,995,437
2021-03-0421.2521.3121.6520.861,572,645
2021-03-0322.121.3322.1421.311,113,604
2021-03-0222.2122.0122.2321.842,010,230
2021-03-0121.8622.322.46521.641,491,409
2021-02-262221.6622.2921.44221,764,473
2021-02-2522.721.9622.7121.791,366,927
2021-02-2422.3622.6622.8422.21,441,792
2021-02-2321.6422.21522.421.291,635,345
2021-02-2221.9822.0122.4121.781,445,861
2021-02-1922.4922.2122.7822.14111,212,946
2021-02-1822.4422.2622.521.812,023,361
2021-02-1722.0222.8622.9821.772,877,044
2021-02-1622.0221.9422.6921.713,548,179
2021-02-1521.7921.9121.9721.263,557,146
2021-02-1221.7921.9121.9721.263,546,742
2021-02-1122.7822.072321.55164,235,730
2021-02-1023.2423.0323.5322.82681,361,381
2021-02-0923.9822.9523.9922.892,085,522
2021-02-0823.5223.8123.9723.161,653,190
Stock Information

Exelixis Inc. Company Name:

EXEL Stock Symbol:

NASDAQ Market:

Exelixis Inc. Website:

EXEL Quote, Trading Chart, Exelixis Inc.

MENU
EXEL EXEL Quote EXEL Short EXEL News EXEL Articles EXEL Message Board
Get EXEL Alerts

News, Short Squeeze, Breakout and More Instantly...

Stock Investor Wire
RECENT EXEL NEWS
  • EXEL - Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

    – CHMP recommendation follows U.S. FDA approval of CABOMETYX in combination with OPDIVO in January – Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use...

  • EXEL - Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March

    Presentations to be webcast on www.exelixis.com Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor conferences in ...

  • EXEL - Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

    – U.S. FDA designation based on an interim analysis of the phase 3 COSMIC-311 pivotal trial, in which cabozantinib demonstrated significant improvement in progression-free survival – – Exelixis expects to submit supplementary New Drug App...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Sign up or login to continue

Sign up or login to continue.


Forgot password?




WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News